SCHEMBL1968107

SCHEMBL1968107

CCOC(=O)c1c(O)c2cccn2n(Cc2ccccc2F)c1=O

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.50
ALDH1A1 P00352 7/20 0.48
LMNA P02545 4/20 0.47
TP53 P04637 2/20 0.46
RXFP1 Q9HBX9 2/20 0.46
KMT2A Q03164 6/20 0.46
MEN1 O00255 4/20 0.46
RECQL P46063 1/20 0.46
HTT P42858 1/20 0.45
POLB P06746 1/20 0.43
NPC1 O15118 2/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 2/20 0.42
RAB9A P51151 1/20 0.42
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1968973 0.89 ALDH1A1 (0.43) KDM4EALDH1A1LMNARXFP1KMT2A
SCHEMBL1966882 0.88 ALDH1A1 (0.46) KDM4EALDH1A1LMNAKMT2AMEN1
SCHEMBL1965997 0.87 KDM4E (0.50) KDM4EALDH1A1LMNAKMT2AMEN1
SCHEMBL1965742 0.87 KDM4E (0.47) KDM4EALDH1A1LMNARXFP1KMT2A
SCHEMBL1967350 0.84 KDM4E (0.54) KDM4EALDH1A1LMNARXFP1KMT2A
SCHEMBL1965910 0.84 ALDH1A1 (0.47) KDM4EALDH1A1LMNAKMT2AMEN1
SCHEMBL1966018 0.81 LMNA (0.49) KDM4EALDH1A1LMNATP53KMT2A
SCHEMBL1967127 0.81 KDM4E (0.48) KDM4EALDH1A1LMNATP53KMT2A
SCHEMBL1966099 0.79 KDM4E (0.44) KDM4EALDH1A1LMNAKMT2AMEN1
SCHEMBL1968371 0.79 KDM4E (0.47) KDM4EALDH1A1LMNARXFP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 KDM4E 471/4885ALDH1A1 268/4885LMNA 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.